Head to Head Review: Integra LifeSciences (NASDAQ:IART) vs. EDAP TMS (NASDAQ:EDAP)

Integra LifeSciences (NASDAQ:IART) and EDAP TMS (NASDAQ:EDAP) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, dividends, analyst recommendations and valuation.

Profitability

This table compares Integra LifeSciences and EDAP TMS’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Integra LifeSciences	-30.87%	12.15%	4.32%
EDAP TMS	-34.45%	-51.42%	-26.43%

Earnings and Valuation

This table compares Integra LifeSciences and EDAP TMS”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Integra LifeSciences	$1.61 billion	0.68	-$6.94 million	($6.53)	-2.15
EDAP TMS	$69.18 million	0.80	-$20.58 million	($0.62)	-2.38

Integra LifeSciences has higher revenue and earnings than EDAP TMS. EDAP TMS is trading at a lower price-to-earnings ratio than Integra LifeSciences, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

84.8% of Integra LifeSciences shares are held by institutional investors. Comparatively, 62.7% of EDAP TMS shares are held by institutional investors. 3.5% of Integra LifeSciences shares are held by company insiders. Comparatively, 0.2% of EDAP TMS shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Risk & Volatility

Integra LifeSciences has a beta of 1.16, meaning that its share price is 16% more volatile than the S&P 500. Comparatively, EDAP TMS has a beta of -0.09, meaning that its share price is 109% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Integra LifeSciences and EDAP TMS, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Integra LifeSciences	4	3	2	0	1.78
EDAP TMS	0	2	1	0	2.33

Integra LifeSciences currently has a consensus price target of $18.6250, suggesting a potential upside of 32.56%. EDAP TMS has a consensus price target of $8.50, suggesting a potential upside of 476.27%. Given EDAP TMS’s stronger consensus rating and higher probable upside, analysts plainly believe EDAP TMS is more favorable than Integra LifeSciences.

Summary

Integra LifeSciences beats EDAP TMS on 10 of the 14 factors compared between the two stocks.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute wounds; and surgical tissue repair products for hernia, tendon, peripheral nerve repair and protection. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.

About EDAP TMS

EDAP TMS SA is a holding company, which, through its subsidiary, engages in the development, production, and marketing of minimally invasive medical devices for urological diseases. It operates through the High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) segments. The HIFU segment develops, manufactures, and markets devices for the minimally invasive ablation of certain types of localized tumors using HIFU technology. The UDS segment focuses on the development, marketing, manufacturing, and servicing of medical devices for the minimally invasive diagnosis or treatment of urological disorders, mainly urinary stones, and other clinical indications. The company was founded on December 3, 1979 and is headquartered in Vaulx-en-Velin, France.